EUCTR2008-000912-34-GB进行中（未招募）不适用
A PHASE 2 STUDY OF THE ANTI-TUMOUR ACTIVITY AND SAFETY OF PROLARIX™ IN HEPATOCELLULAR CARCINOMA (HCC)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject must be >=18 years of age.
- •Subject must have a histologic or cytologic diagnosis of HCC and be considered unsuitable for resection or other potentially curative options (eg, liver transplant, curative radiofrequency ablation). [Note: Subjects who have not yet had a tissue diagnosis may enter the Screening phase of the study if 1) their clinical presentation is considered highly suggestive of HCC by the principal investigator and 2) a tissue diagnosis is considered necessary for their management (subjects for whom a tissue diagnosis is not considered essential for their management should not be enrolled on this study). A tissue diagnosis must be obtained prior to the entry of any subject into the treatment phase of the study. Subjects for whom the principal investigator deems core biopsy to be indicated (as opposed to fine needle aspiration) will be requested to provide informed consent for a second pass biopsy (ie, in addition to the first pass biopsy for tissue diagnosis) for quantification of enzyme DT diaphorase (NQO2) activity. The second pass biopsy is optional and subjects refusing a second pass biopsy may be enrolled in the study and will be treated identically to those accepting the second pass biopsy]
- •Subject must have a measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) on CT scan in at least one site which has not received radiation or any other local therapy [eg, transcatheter arterial chemoembolisation (TACE), radiofrequency ablation, local injection]. (Note: Subjects who have received local therapies will be allowed to participate provided that they have a target lesion which has not been subjected to local therapy. Subjects who have received TACE must have a target lesion outside of the vascular territory subjected to chemoembolisation).
- •Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
- •Subject has had no other active malignancy within the past three years [other than non melanomatous skin cancer or carcinoma in situ (CIS) of the breast, bladder or uterine cervix. Subjects with Ta (non-invasive papillary carcinoma) or Tis (sessile carcinoma in situ) bladder cancer are allowed]
- •Subject has a minimum life expectancy of at least three months as determined by the investigator.
- •Subject has adequate bone marrow function (ie, haemoglobin =9 g/dL, granulocytes =1500/mm3, platelets =75,000/mm3).
- •Prothrombin time (PT)-international normalised ratio (INR) <=2.3 or PT <=6 seconds above control. (Note: Subjects who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that their INR is between 2.0 and 3.0).
- •Subject has adequate renal function (ie, serum creatinine clearance is normal or calculated creatinine clearance is =60 mL/min).
- •Subject has adequate hepatic function (ie, bilirubin =2x upper limit of normal (ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase <=5xULN). (Also see exclusion for Child-Pugh class C below).
- •Male subjects and females of childbearing potential must agree to use an adequate method of contraception from the time of initiation of treatment through study participation and for 3 months after release from the study.
- •Subject is able to give informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
排除标准
- •Any prior or current systemic pharmacotherapy for HCC (cytotoxic, targeted or biologic). (Note: TACE is not considered to be systemic pharmacotherapy for the purpose of this study.)
- •Subject has an absolute contraindication to receiving CT contrast media. (Note: Subjects with a history of minor contrast reactions may be pre-medicated prior to contrast administration in accordance with local or institutional practice.)
- •Subject has Child-Pugh Class C hepatic impairment.
- •Subject has received an investigational drug within 30 days of enrolment in the study.
- •Females of childbearing potential unless using adequate contraception.
- •Pregnant or lactating females.
- •Major variceal bleeding in the last 30 days.
- •Subjects with a known history of human immunodeficiency virus (HIV) infection.
研究者
相似试验
进行中（未招募）
不适用
A PHASE 2 STUDY OF THE ANTI-TUMOUR ACTIVITY AND SAFETY OF PROLARIX™ IN HEPATOCELLULAR CARCINOMA (HCC)EUCTR2008-000912-34-BEProtherics Development Medicines Ltd20
进行中（未招募）
1 期
Selinexor in the treatment of patients with Refractory and/or Relapsed Richter's TransformatioEUCTR2014-001240-38-GBKaryopharm Therapeutics Inc.50
进行中（未招募）
1 期
Richters TransformatioInitial and Refractory/Relapsed Richters Transformation (RT)MedDRA version: 18.0Level: PTClassification code 10058728Term: Richter's syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001240-38-DEKaryopharm Therapeutics, Inc.50
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumorslocally advanced (primary or recurrent) or metastatic solid tumors with a pathogenic or likely pathogenic germline or loss-of-function somatic BRCA1, or BRCA2, or ATM gene defectMedDRA version: 20.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2018-000345-39-NLPfizer Inc., 235 East 42nd Street, New York, NY 10017541
已完成
2 期
A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant TumorsNL-OMON48840Pfizer22